PLYMOUTH MEETING, Pa. , Nov. 18, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that it will participate in the following investor conferences: Piper Sandler 37th Annual Healthcare Conference (New York, NY) Date: Tuesday, December 2 Time: 8:30-8:55 AM ET Format: Fireside Chat Webcast:  https://bit.ly/44af19l (live webcast ...

Core Insights - INOVIO is set to release its third quarter 2025 financial results on November 10, 2025, after market close, followed by a live conference call and webcast at 4:30 p.m. ET to discuss the results and provide a business update [1]. Company Overview - INOVIO is a biotechnology company focused on developing and commercializing DNA medicines aimed at treating and protecting individuals from HPV-related diseases, cancers, and infectious diseases [3]. - The company's technology is designed to optimize the design and delivery of innovative DNA medicines that enable the body to produce its own disease-fighting tools [3]. Event Details - The live webcast for the financial results will be available online and will include a live Q&A session with analysts, with the event being archived for 90 days for replay [2].

Core Insights - INOVIO is participating in a virtual fireside chat at the upcoming Stephens Biotechnology Virtual Fireside Chat Conference, where management will also hold one-on-one meetings with investors [1][2]. Company Overview - INOVIO is a biotechnology company focused on developing and commercializing DNA medicines aimed at treating and protecting individuals from HPV-related diseases, cancer, and infectious diseases [3][5]. - The company's technology enhances the design and delivery of innovative DNA medicines that instruct the body to produce its own disease-fighting tools [3].

Core Insights - INOVIO is a biotechnology company focused on developing and commercializing DNA medicines for HPV-associated diseases, cancer, and infectious diseases [3] Group 1: Conference Details - INOVIO announced a pre-recorded presentation will be available on demand as part of the H.C. Wainwright 27th Annual Global Investment Conference in New York [1] - The presentation will be accessible starting September 5, 2025, at 7:00 AM ET and will remain available for 90 days [2] - INOVIO's management team will also conduct in-person one-on-one meetings with investors during the conference [1] Group 2: Company Overview - INOVIO's technology focuses on optimizing the design and delivery of innovative DNA medicines that enable the body to produce its own disease-fighting tools [3] - The company aims to help treat and protect individuals from HPV-related diseases, cancer, and infectious diseases [3]

Core Viewpoint - INOVIO Pharmaceuticals, Inc. has announced a public offering of 14,285,715 shares of common stock and accompanying Series A and Series B warrants, priced at $1.75 per share, aiming to raise approximately $25 million before expenses [1][2]. Group 1: Offering Details - The public offering includes 14,285,715 shares of common stock and warrants to purchase an equal number of shares at an exercise price of $1.75 [1]. - The offering is expected to close on or about July 7, 2025, pending customary closing conditions [1]. - Underwriters have a 30-day option to purchase up to 2,142,857 additional shares and warrants at the public offering price [1]. Group 2: Financial Aspects - Gross proceeds from the offering are anticipated to be approximately $25 million, excluding underwriting discounts and commissions [2]. - The offering is being managed by Piper Sandler & Co. as the sole active book-running manager, with Oppenheimer & Co. Inc. as a passive bookrunner [2]. Group 3: Regulatory Information - A shelf registration statement for the offering was filed with the SEC on November 9, 2023, and was declared effective on January 31, 2024 [3]. - The offering is conducted through a written prospectus and prospectus supplement available on the SEC's website [3]. Group 4: Company Overview - INOVIO is focused on developing and commercializing DNA medicines aimed at treating HPV-related diseases, cancer, and infectious diseases [5]. - The company's technology is designed to optimize the design and delivery of DNA medicines that enable the body to produce its own disease-fighting tools [5].

Core Points - INOVIO, a biotechnology company, focuses on developing and commercializing DNA medicines for HPV-associated diseases, cancers, and infectious diseases [1][3] - The company will release its first quarter 2025 financial results on May 13, 2025, after market close [1] - A live conference call and webcast will follow the financial results release at 4:30 p.m. ET, including a Q&A session with analysts [1][2] Company Overview - INOVIO's technology is designed to optimize the design and delivery of DNA medicines that enable the body to produce its own disease-fighting tools [3] - The company aims to protect and treat individuals from HPV-related diseases and other infectious diseases through its innovative approach [3]